567 related articles for article (PubMed ID: 15969866)
1. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel.
Shepherd J; Betteridge J; Van Gaal L;
Curr Med Res Opin; 2005 May; 21(5):665-82. PubMed ID: 15969866
[TBL] [Abstract][Full Text] [Related]
2. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
3. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
Chapman MJ; Assmann G; Fruchart JC; Shepherd J; Sirtori C;
Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528
[TBL] [Abstract][Full Text] [Related]
4. Dyslipidaemia in diabetic patients: time for a rethink.
Shepherd J
Diabetes Obes Metab; 2007 Sep; 9(5):609-16. PubMed ID: 17697054
[TBL] [Abstract][Full Text] [Related]
5. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
Reiner Z
Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
[TBL] [Abstract][Full Text] [Related]
6. Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.
Kones R
Vasc Health Risk Manag; 2013; 9():617-70. PubMed ID: 24174878
[TBL] [Abstract][Full Text] [Related]
7. Beyond the statins: new therapeutic perspectives in cardiovascular disease prevention.
Chapman MJ
Cardiovasc Drugs Ther; 2005 Mar; 19(2):135-9. PubMed ID: 16025232
[TBL] [Abstract][Full Text] [Related]
8. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
Jacobson TA
Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
[TBL] [Abstract][Full Text] [Related]
9. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
10. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.
Keating GM; Croom KF
Drugs; 2007; 67(1):121-53. PubMed ID: 17209672
[TBL] [Abstract][Full Text] [Related]
11. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
12. The therapeutic role of niacin in dyslipidemia management.
Boden WE; Sidhu MS; Toth PP
J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):141-58. PubMed ID: 24363242
[TBL] [Abstract][Full Text] [Related]
13. Diabetic dyslipidemia.
Kreisberg RA
Am J Cardiol; 1998 Dec; 82(12A):67U-73U; discussion 85U-86U. PubMed ID: 9915665
[TBL] [Abstract][Full Text] [Related]
14. Management of dyslipidemia in adults with diabetes.
Haffner SM
Diabetes Care; 1998 Jan; 21(1):160-78. PubMed ID: 9538988
[TBL] [Abstract][Full Text] [Related]
15. Niacin as a component of combination therapy for dyslipidemia.
Miller M
Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
[TBL] [Abstract][Full Text] [Related]
16. Management of hypercholesterolaemia in the patient with diabetes.
Packard C; Olsson AG
Int J Clin Pract Suppl; 2002 Jul; (130):27-32. PubMed ID: 12296606
[TBL] [Abstract][Full Text] [Related]
17. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.
Keating GM; Ormrod D
Drugs; 2002; 62(13):1909-44. PubMed ID: 12215067
[TBL] [Abstract][Full Text] [Related]
18. What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
Ahmed MH
J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):858-60. PubMed ID: 20686417
[TBL] [Abstract][Full Text] [Related]
19. Advances in the understanding and management of dyslipidemia: using niacin-based therapies.
Ito MK
Am J Health Syst Pharm; 2003 Jul; 60(13 Suppl 2):S15-21; quiz S25. PubMed ID: 12901026
[TBL] [Abstract][Full Text] [Related]
20. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
Evans M; Roberts A; Davies S; Rees A
Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
